The DOI matches its Crossref record; 217 of the 217 references it cites were found in a registry or an index.
Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma
Open accessAbstract
Hepatocellular carcinoma (HCC) is an aggressive human cancer with increasing incidence worldwide. Multiple efforts have been made to explore pharmaceutical therapies to treat HCC, such as targeted tyrosine kinase inhibitors, immune based therapies and combination of chemotherapy. However, limitations exist in current strategies including chemoresistance for instance. Tumor initiation and progression is driven by reprogramming of metabolism, in particular during HCC development. Recently, metabolic associated fatty liver disease (MAFLD), a reappraisal of new nomenclature for non-alcoholic fatty liver disease (NAFLD), indicates growing appreciation of metabolism in the pathogenesis of liver disease, including HCC, thereby suggesting new strategies by targeting abnormal metabolism for HCC treatment. In this review, we introduce directions by highlighting the metabolic targets in glucose, fatty acid, amino acid and glutamine metabolism, which are suitable for HCC pharmaceutical intervention. We also summarize and discuss current pharmaceutical agents and studies targeting deregulated metabolism during HCC treatment. Furthermore, opportunities and challenges in the discovery and development of HCC therapy targeting metabolism are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–217 of 217
Chan, K., Kuo, C., Hsu, J., Chiou, M., Wang, Y., Wu, T., Lee, C., Wu, T.-J., Chou, H., & Lee, W. (2016) · Liver International · doi:10.1111/liv.13280 · Cited by 38
Antitumor and chemosensitizing action of 3-bromopyruvate: Implication of deregulated metabolism
Yadav, S., Pandey, S. K., Kumar, A., Kujur, P. K., Singh, R. P., & Singh, S. M. (2017) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2017.04.015 · Cited by 37
Cho, J., Kim, G., Mansfield, B. C., & CHOU, J. Y. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.03.083 · Cited by 37
HIF-1 suppresses lipid catabolism to promote cancer progression
Zhang, H. (2015) · Molecular & Cellular Oncology · doi:10.4161/23723556.2014.980184 · Cited by 31
Li, J., Chen, K., Wang, F., Dai, W., Li, S., Feng, J., Wu, L., Liu, T., Xu, S., Xia, Y., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17469 · Cited by 30
Sirtuin signaling controls mitochondrial function in glycogen storage disease type Ia
Cho, J., Kim, G., Mansfield, B. C., & CHOU, J. Y. (2018) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-018-0192-1 · Cited by 29
Pseudogene CYP4Z2P 3′UTR promotes angiogenesis in breast cancer
Zheng, L., Li, X., Gu, Y., Ma, Y., & Xi, T. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.09.112 · Cited by 27
Self-citationTian, G., Zang, S., Wang, L., Luo, Y., Shi, J., & Lou, G. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000438593 · Cited by 26
Falchook, G. S., Patel, M. R., Infante, J. R., Arkenau, H., Dean, E. J., Brenner, A. J., Borazanci, E. H., Lopez, J. S., Moore, K. N., Schmid, P., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-ct153 · Cited by 25
Qiang, L., Kon, N., Zhao, W., Jiang, L., Knight, C. M., Welch, C. L., Pajvani, U. B., Gu, W. J., & Accili, D. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.05.025 · Cited by 24
Wei, Q., Mei, L., Yang, Y., Ma, H., Chen, H., Zhang, H., & Zhou, J. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.03.014 · Cited by 23
He, L., Cai, X.-F., Cheng, S., Zhou, H., Zhang, Z., Ren, J., Ren, F., Yang, Q., Tao, N., & Chen, J. (2019) · Oncology Letters · doi:10.3892/ol.2019.10174 · Cited by 19
Shimizu, Y., Tamura, T., Kemmochi, A., Owada, Y., Ozawa, Y., Hisakura, K., Matsuzaka, T., Shimano, H., Nakano, N., Sakashita, S., et al. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15239 · Cited by 15
Zhang, H., Guo, X., Dai, J., Wu, Y., Ge, N., Yang, Y., Ji, J., & Zhang, H. (2014) · Medical Oncology · doi:10.1007/s12032-014-0278-z · Cited by 13
Wattanavanitchakorn, S., Ansari, I. H., Azzouny, M. E., Longacre, M. J., Stoker, S. W., MacDonald, M. J., & Jitrapakdee, S. (2019) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2019.108124 · Cited by 9
Duke, G., Wagman, A. S., BUCKLEY, D. I., McCulloch, W. F., & Kemble, G. W. (2017) · Journal of Hepatology · doi:10.1016/s0168-8278(17)30460-9 · Cited by 6
Expression of Malic Enzymes in Sebaceous Lesions
Su, T.-F., & Gao, H. (2015) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000000451 · Cited by 4
Cited by
The PI3K/Akt Pathway and Glucose Metabolism: A Dangerous Liaison in Cancer
Fontana, F., Giannitti, G., Marchesi, S., & Limonta, P. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.89942 · Cited by 280
Gajos-Michniewicz, A., & Czyz, M. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2023.02.050 · Cited by 89
Fu, Y., Li, J., Cai, W., Huang, Y., Liu, X., Ma, Z., Tang, Z., Bian, X., Zheng, J., Jiang, J., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.11.018 · Cited by 48
Liu, L., Zhou, Y., Liu, J., Zhang, X., He, C., Zeng, X., Dejenie, R., Zeb, U., Zeng, Q., Liu, L., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07005-0 · Cited by 13
Self-citationCitalopram exhibits immune-dependent anti-tumor effects by modulating C5aR1+ TAMs
Dong, F., Zhang, S., Song, K., Jiang, L., Hu, L.-P., Li, Q., Zhang, X.-L., Li, J., Feng, M., Cai, Z.-W., et al. (2026) · eLife · doi:10.7554/elife.103016 · Cited by 2
Self-citation
Metadata
- Authors
- Du, D., Liu, C., Qin, M., Zhang, X., Xi, T., Yuan, S., Hao, H., & Xiong, J.
- Venue
- Acta Pharmaceutica Sinica B
- Publisher
- Elsevier BV
- Published
- 2022-02
- Volume
- 12
- Issue
- 2
- Pages
- 558-580
- ISSN
- 2211-3835 (ISSN-L)
- OpenAlex
- W3204325474
- Cited by
- 643
- References
- 217
- FWCI
- 26.40
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.